Literature DB >> 29273248

Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Sabine Pellett1, William H Tepp2, Guangyun Lin3, Eric A Johnson4.   

Abstract

Botulinum neurotoxin (BoNT) type FA is the only known naturally occurring chimeric BoNT of domains of BoNT/A and BoNT/F. BoNT/FA consists of an F5-like light chain (LC), a unique heavy chain (HC) translocation domain, and a HC receptor binding domain similar to BoNT/A1. Previous analyses of purified BoNT/FA have indicated a 5-10-fold greater potency in cultured human or rat neurons as compared to BoNT/A1 and a 400-500-fold greater potency compared to BoNT/B1. However, in vivo potency in mice was about 5-fold lower than BoNT/A1 or/B1. In this report, species specificity was examined by cell-based assays using primary neurons from mice and examining VAMP1 and 2 cleavage. The data indicated similar potency of BoNT/FA in primary mouse spinal cord neurons as previously observed in primary rat and human induced pluripotent stem cell (hiPSC) derived neuronal cell models, and equal enzymatic cleavage of mouse VAMP1 and 2 isoforms. Since the duration of action of BoNTs is due to continuous enzymatic activity of the LC in the neuronal cytosol, BoNT/FA was expected to have a short duration of action due to its F-type LC. In this report the duration of action of BoNT/FA was compared to that of BoNT/F1,/F5, and/B1 in both hiPSC derived neurons and in the in vivo mouse model. The data indicate a duration of action of BoNT/FA similar to BoNT/B1, while BoNT/F5 had a short duration of action similar to BoNT/F1.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botulinum neurotoxin; Botulinum neurotoxin FA; Botulinum neurotoxin H; Duration; Recovery; VAMP

Mesh:

Substances:

Year:  2017        PMID: 29273248      PMCID: PMC5911199          DOI: 10.1016/j.toxicon.2017.12.048

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  50 in total

1.  Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin.

Authors:  S Prabakaran; W Tepp; B R DasGupta
Journal:  Toxicon       Date:  2001-10       Impact factor: 3.033

Review 2.  Botulinum neurotoxin: a marvel of protein design.

Authors:  Mauricio Montal
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 3.  The typing of botulinal neurotoxins.

Authors:  D F Giménez; J A Giménez
Journal:  Int J Food Microbiol       Date:  1995-09       Impact factor: 5.277

4.  Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.

Authors:  Andreas Rummel
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

5.  Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5.

Authors:  Suzanne R Kalb; Jakub Baudys; Robert P Webb; Patrick Wright; Theresa J Smith; Leonard A Smith; Rafael Fernández; Brian H Raphael; Susan E Maslanka; James L Pirkle; John R Barr
Journal:  FEBS Lett       Date:  2011-12-09       Impact factor: 4.124

6.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

7.  Molecular characterization of a novel botulinum neurotoxin type H gene.

Authors:  Nir Dover; Jason R Barash; Karen K Hill; Gary Xie; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

8.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Authors:  Jason R Barash; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

9.  Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Authors:  Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

Review 10.  Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature.

Authors:  Michael W Peck; Theresa J Smith; Fabrizio Anniballi; John W Austin; Luca Bano; Marite Bradshaw; Paula Cuervo; Luisa W Cheng; Yagmur Derman; Brigitte G Dorner; Audrey Fisher; Karen K Hill; Suzanne R Kalb; Hannu Korkeala; Miia Lindström; Florigio Lista; Carolina Lúquez; Christelle Mazuet; Marco Pirazzini; Michel R Popoff; Ornella Rossetto; Andreas Rummel; Dorothea Sesardic; Bal Ram Singh; Sandra C Stringer
Journal:  Toxins (Basel)       Date:  2017-01-18       Impact factor: 4.546

View more
  9 in total

1.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

2.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

3.  Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  FEBS Lett       Date:  2019-07-04       Impact factor: 4.124

4.  Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.

Authors:  Gavin Hackett; Kevin Moore; David Burgin; Fraser Hornby; Bryony Gray; Mark Elliott; Imran Mir; Matthew Beard
Journal:  Toxins (Basel)       Date:  2018-05-11       Impact factor: 4.546

Review 5.  Engineering of Botulinum Neurotoxins for Biomedical Applications.

Authors:  Robert P Webb
Journal:  Toxins (Basel)       Date:  2018-06-06       Impact factor: 4.546

Review 6.  Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  Toxins (Basel)       Date:  2019-12-07       Impact factor: 4.546

7.  The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.

Authors:  Sabine Pellett; Marite Bradshaw; William H Tepp; Christina L Pier; Regina C M Whitemarsh; Chen Chen; Joseph T Barbieri; Eric A Johnson
Journal:  MBio       Date:  2018-03-27       Impact factor: 7.867

Review 8.  Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.

Authors:  Domenico Azarnia Tehran; Marco Pirazzini
Journal:  Toxins (Basel)       Date:  2018-05-10       Impact factor: 4.546

Review 9.  Light Chain Diversity among the Botulinum Neurotoxins.

Authors:  Alexander P Gardner; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2018-07-02       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.